Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
| ▸ | BCL9 | O00512 | 2/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30722047 | 1.00 | PDE4B (0.52) | PDE4BTRPV3HRH3BCL9CTNNB1 | |
| SCHEMBL26985427 | 0.94 | PDE4B (0.58) | PDE4BTRPV3HRH3USP30DPP4 | |
| SCHEMBL25251089 | 0.89 | USP30 (0.48) | PDE4BHRH3USP30DPP4 | |
| SCHEMBL26985167 | 0.87 | NAMPT (0.51) | PDE4BTRPV3HRH3DPP4MAPT | |
| SCHEMBL24196363 | 0.86 | PDE4B (0.52) | PDE4BTRPV3HRH3BCL9CTNNB1 | |
| SCHEMBL21962362 | 0.86 | PDE4B (0.49) | PDE4BTRPV3HRH3BCL9CTNNB1 | |
| SCHEMBL14225752 | 0.85 | PDE4B (0.53) | PDE4BTRPV3BCL9CTNNB1FPR2 | |
| SCHEMBL15650585 | 0.85 | PDE4B (0.53) | PDE4BTRPV3HRH3BCL9CTNNB1 | |
| SCHEMBL31386180 | 0.84 | PDE4B (0.52) | PDE4BTRPV3HRH3BCL9CTNNB1 | |
| SCHEMBL22810473 | 0.83 | PDE4B (0.52) | PDE4BTRPV3USP30HPGDSJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353862-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-11-20 | — | — | US | disclosed |
| US-12404283-B2 | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | ANIMA BIOTECH INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4547671-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-4547672-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250129100-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2024010761-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024010762-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024010761-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024010762-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2024-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129100-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | PDE4B 3361/4885TRPV3 4792/4885HRH3 4838/4885 |
| US-20250353862-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | PDE4B 3361/4885TRPV3 4792/4885HRH3 4838/4885 |
| US-12404283-B2 | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | MYC, MYCBP, MYCBP2 | PDE4B 3361/4885TRPV3 4792/4885HRH3 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.